Filing Details

Accession Number:
0001567619-19-020529
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-06 17:16:23
Reporting Period:
2019-11-04
Accepted Time:
2019-11-06 17:16:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1184149 W Jonathan Ayers One Idexx Drive
Westbrook ME 04092
Yes No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-11-04 53,820 $45.84 1,079,784 No 4 M Direct
Common Stock Disposition 2019-11-04 23,375 $278.90 1,056,409 No 4 S Direct
Common Stock Disposition 2019-11-04 26,198 $279.72 1,030,211 No 4 S Direct
Common Stock Disposition 2019-11-04 4,247 $280.47 1,025,964 No 4 S Direct
Common Stock Disposition 2019-11-04 1,891 $279.43 1,024,073 No 4 S Direct
Common Stock Disposition 2019-11-04 3,402 $280.08 1,020,671 No 4 S Direct
Common Stock Disposition 2019-11-04 2,984 $281.74 1,017,687 No 4 S Direct
Common Stock Disposition 2019-11-05 1,300 $277.87 1,016,387 No 4 S Direct
Common Stock Disposition 2019-11-05 3,839 $265.38 1,012,548 No 4 S Direct
Common Stock Disposition 2019-11-05 11,794 $266.54 1,000,754 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2019-11-04 53,820 $0.00 53,820 $45.84
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-02-13 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 138,000 Indirect by Ayers Family Trust
Footnotes
  1. Includes 22 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2019.
  2. Represents the weighted average price of the shares sold ranging from a low of $278.155 to a high of $279.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  3. Represents the weighted average price of the shares sold ranging from a low of $279.16 to a high of $280.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  4. Represents the weighted average price of the shares sold ranging from a low of $280.17 to a high of $280.63 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  5. Represents the weighted average price of the shares sold ranging from a low of $279.01 to a high of $280.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  6. Represents the weighted average price of the shares sold ranging from a low of $280.05 to a high of $280.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  7. Represents the weighted average price of the shares sold ranging from a low of 281.515 to a high of $281.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  8. Represents the weighted average price of the shares sold ranging from a low of 277.55 to a high of $277.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  9. Represents the weighted average price of the shares sold ranging from a low of 265.00 to a high of $266.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  10. Represents the weighted average price of the shares sold ranging from a low of 266.1150 to a high of $267.05 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  11. The number of derivative securities has been revised to reflect the current number available for the reported transaction.
  12. Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  13. Not applicable.